SCHEMBL1702763

SCHEMBL1702763

COc1cccc(NC(=O)Nc2ccc(-c3nccc4[nH]nc(N)c34)cc2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.74
ROCK2 O75116 3/20 0.59
LIMK1 P53667 3/20 0.59
KIT P10721 11/20 0.58
FLT3 P36888 10/20 0.58
LCK P06239 3/20 0.58
CSF1R P07333 3/20 0.58
FLT1 P17948 3/20 0.58
FLT4 P35916 3/20 0.58
PLK4 O00444 2/20 0.58
AURKA O14965 2/20 0.58
INSR P06213 2/20 0.58
MET P08581 2/20 0.58
FGFR1 P11362 2/20 0.58
PRKACA P17612 2/20 0.58
RPS6KB1 P23443 2/20 0.58
MARK3 P27448 2/20 0.58
CSNK1D P48730 2/20 0.58
GSK3B P49841 2/20 0.58
RPS6KA3 P51812 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703112 0.87 KDR (0.83) KDRROCK2LIMK1KITFLT3
SCHEMBL2240322 0.86 KDR (0.66) KDRROCK2LIMK1KITFLT3
SCHEMBL2237406 0.86 KDR (0.78) KDRROCK2LIMK1KITFLT3
SCHEMBL1702941 0.85 KDR (0.75) KDRROCK2LIMK1KITFLT3
SCHEMBL1703314 0.85 KDR (1.00) KDRROCK2LIMK1KITFLT3
SCHEMBL1703611 0.85 KDR (0.78) KDRROCK2LIMK1KITFLT3
SCHEMBL2237920 0.83 KDR (0.83) KDRROCK2LIMK1KITFLT3
SCHEMBL1703065 0.83 KDR (1.00) KDRROCK2LIMK1KITFLT3
SCHEMBL1702820 0.82 KDR (1.00) KDRROCK2LIMK1KITFLT3
SCHEMBL12346318 0.81 KDR (0.76) KDRROCK2LIMK1KITFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP claimed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 EP claimed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US claimed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 WO claimed
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP disclosed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KDR 434/4885ROCK2 292/4885LIMK1 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.